VALNEVA SE (VLA.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:VLA - FR0004056851 - Common Stock
3.869 EUR
+0.05 (+1.28%)
Overall VLA gets a fundamental rating of 2 out of 10. We evaluated VLA against 83 industry peers in the Biotechnology industry. Both the profitability and financial health of VLA have multiple concerns. VLA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year VLA has reported negative net income.
VLA had a negative operating cash flow in the past year.
In the past 5 years VLA always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: VLA reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of -18.09%, VLA is in line with its industry, outperforming 51.81% of the companies in the same industry.
VLA has a Return On Equity (-45.87%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.09% | ||
| ROE | -45.87% | ||
| ROIC | N/A |
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 48.94%, VLA is in line with its industry, outperforming 44.58% of the companies in the same industry.
In the last couple of years the Gross Margin of VLA has declined.
The Profit Margin and Operating Margin are not available for VLA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
2. Health
2.1 Basic Checks
VLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
VLA has more shares outstanding than it did 1 year ago.
VLA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for VLA has been reduced compared to a year ago.
2.2 Solvency
VLA has an Altman-Z score of -0.26. This is a bad value and indicates that VLA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of VLA (-0.26) is comparable to the rest of the industry.
VLA has a Debt/Equity ratio of 0.80. This is a neutral value indicating VLA is somewhat dependend on debt financing.
VLA has a Debt to Equity ratio (0.80) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.26 |
ROIC/WACCN/A
WACC7.63%
2.3 Liquidity
VLA has a Current Ratio of 2.27. This indicates that VLA is financially healthy and has no problem in meeting its short term obligations.
VLA has a Current ratio (2.27) which is in line with its industry peers.
A Quick Ratio of 1.77 indicates that VLA should not have too much problems paying its short term obligations.
VLA's Quick ratio of 1.77 is in line compared to the rest of the industry. VLA outperforms 44.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.77 |
3. Growth
3.1 Past
The earnings per share for VLA have decreased strongly by -1180.00% in the last year.
VLA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.32%.
VLA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.09% yearly.
EPS 1Y (TTM)-1180%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-271.43%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%-35.76%
3.2 Future
VLA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 55.46% yearly.
The Revenue is expected to grow by 17.32% on average over the next years. This is quite good.
EPS Next Y-639.98%
EPS Next 2Y-113.91%
EPS Next 3Y108.86%
EPS Next 5Y55.46%
Revenue Next Year-5.39%
Revenue Next 2Y3.18%
Revenue Next 3Y28.09%
Revenue Next 5Y17.32%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
VLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VLA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VLA's earnings are expected to grow with 108.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-113.91%
EPS Next 3Y108.86%
5. Dividend
5.1 Amount
VLA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:VLA (12/8/2025, 5:29:15 PM)
3.869
+0.05 (+1.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners22.69%
Inst Owner ChangeN/A
Ins Owners0.22%
Ins Owner ChangeN/A
Market Cap332.41M
Revenue(TTM)169.58M
Net Income(TTM)-85.51M
Analysts81.82
Price Target7.21 (86.35%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.78%
Min EPS beat(2)56.68%
Max EPS beat(2)62.87%
EPS beat(4)3
Avg EPS beat(4)14.13%
Min EPS beat(4)-115.24%
Max EPS beat(4)62.87%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)-23.48%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)21.69%
Min Revenue beat(2)16.4%
Max Revenue beat(2)26.97%
Revenue beat(4)3
Avg Revenue beat(4)10.09%
Min Revenue beat(4)-4.78%
Max Revenue beat(4)26.97%
Revenue beat(8)4
Avg Revenue beat(8)1.3%
Revenue beat(12)7
Avg Revenue beat(12)19.63%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.51%
PT rev (3m)-1.97%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10%
EPS NY rev (1m)-2.87%
EPS NY rev (3m)-4.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.54%
Revenue NY rev (1m)-1.66%
Revenue NY rev (3m)-9.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.14 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.78 | ||
| P/tB | 2.04 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS3.39
BVpS2.17
TBVpS1.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.09% | ||
| ROE | -45.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.94% | ||
| FCFM | N/A |
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 71.71% | ||
| Cap/Sales | 5.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.77 | ||
| Altman-Z | -0.26 |
F-Score4
WACC7.63%
ROIC/WACCN/A
Cap/Depr(3y)101.58%
Cap/Depr(5y)231.17%
Cap/Sales(3y)9.04%
Cap/Sales(5y)14.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1180%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-271.43%
EPS Next Y-639.98%
EPS Next 2Y-113.91%
EPS Next 3Y108.86%
EPS Next 5Y55.46%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%-35.76%
Revenue Next Year-5.39%
Revenue Next 2Y3.18%
Revenue Next 3Y28.09%
Revenue Next 5Y17.32%
EBIT growth 1Y-49.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-294.29%
EBIT Next 3Y47.89%
EBIT Next 5Y30.38%
FCF growth 1Y88.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.27%
OCF growth 3YN/A
OCF growth 5YN/A
VALNEVA SE / VLA.PA FAQ
Can you provide the ChartMill fundamental rating for VALNEVA SE?
ChartMill assigns a fundamental rating of 2 / 10 to VLA.PA.
What is the valuation status of VALNEVA SE (VLA.PA) stock?
ChartMill assigns a valuation rating of 1 / 10 to VALNEVA SE (VLA.PA). This can be considered as Overvalued.
Can you provide the profitability details for VALNEVA SE?
VALNEVA SE (VLA.PA) has a profitability rating of 1 / 10.
Can you provide the financial health for VLA stock?
The financial health rating of VALNEVA SE (VLA.PA) is 3 / 10.